Recent patents on CNS drug discovery最新文献_第2页

Editorial (Thematic Issue: From Old Cannabinoids to Emerging New Synthetic Derivatives with Potential Therapeutic Application in Neurological Disorders). 社论(专题问题:从旧大麻素到新兴的新合成衍生物，在神经系统疾病中具有潜在的治疗应用)。

Recent patents on CNS drug discovery Pub Date : 2016-01-01 DOI: 10.2174/157488981002160919201100

Anna M Malfitano

引用次数: 0

Exosome-based strategies for Diagnosis and Therapy. 基于外泌体的诊断和治疗策略。

Recent patents on CNS drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574889810666150702124059

Lorena Urbanelli, Sandra Buratta, Krizia Sagini, Giuseppina Ferrara, Marco Lanni, Carla Emiliani

{"title":"Exosome-based strategies for Diagnosis and Therapy.","authors":"Lorena Urbanelli, Sandra Buratta, Krizia Sagini, Giuseppina Ferrara, Marco Lanni, Carla Emiliani","doi":"10.2174/1574889810666150702124059","DOIUrl":"https://doi.org/10.2174/1574889810666150702124059","url":null,"abstract":"Exosomes are small extracellular vesicles (30-120 nm) of endosomal origin, which are gaining the attention of the scientific community. Originally considered only a waste disposal system, they are now emerging as another class of signal mediators. Exosomes are secreted by any cell type and retrieved in every body fluid, such as blood, urine, saliva and amniotic liquid. Remarkably, their biochemical content includes not only lipids and proteins, but also nucleic acids, mainly miRNA and mRNA, with a few reports also indicating the presence of genomic and mitochondrial DNA. Their properties have stimulated extensive research to exploit them as a source of biomarkers for the diagnosis and the follow-up of several pathologies. Furthermore, exosomes are relatively robust and stable, so they appear attractive as gene and drug delivery vehicles. They have also revealed immunomodulatory and regenerative properties, which are encouraging their application for therapeutic purposes. Several issues remain to be addressed: exosome isolation is still time consuming and unsatisfactorily reproducible, making it difficult to compare results among laboratories, improve our knowledge of their physiological function and correlate their features with pathological outcomes. Nevertheless, the number of patents trying to address these problems is growing exponentially and many novelties will reach the scientific community in the next few years. ","PeriodicalId":87737,"journal":{"name":"Recent patents on CNS drug discovery","volume":"10 1","pages":"10-27"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574889810666150702124059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33974020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 95

The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery. 老年髋部骨折术后谵妄的防治。

Recent patents on CNS drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574889810666150216152624

Antonio Martocchia, Martina Curto, Fabrizia Comite, Sergio Scaccianoce, Paolo Girardi, Stefano Ferracuti, Ferdinando Nicoletti, Paolo Falaschi

{"title":"The Prevention and Treatment of Delirium in Elderly Patients Following Hip Fracture Surgery.","authors":"Antonio Martocchia, Martina Curto, Fabrizia Comite, Sergio Scaccianoce, Paolo Girardi, Stefano Ferracuti, Ferdinando Nicoletti, Paolo Falaschi","doi":"10.2174/1574889810666150216152624","DOIUrl":"https://doi.org/10.2174/1574889810666150216152624","url":null,"abstract":"Osteoporotic hip fracture needs a specific approach and treatment, since elderly patients are at high risk for adverse outcomes after surgery. In particular, delirium often occurs in the peri-operative period, and it is associated with death, hospital-acquired complications, persistent cognitive impairments, poor functional recovery after surgery and increased healthcare costs. The pre-operative assessment of the risk factors for delirium improves the preventive measures. The delirium diagnostic tools should be included in the standard of orthogeriatric cure for hip fracture. Given the increasing complexity of the clinical pictures, we present a review of the available treatment options for delirium in patients with hip fracture. The metabolic pre-operative disorders and the management of co-morbid diseases are specific targets of treatment in order to optimize the outcomes after surgery. In particular, elderly patients with Alzheimer's disease are highly vulnerable to hip fracture and delirium, and they are severely frail with reduced physiologic reserves. An integrated approach combining environmental and pharmacological strategies is useful in the delirium treatment, with a close collaboration between the orthopedic and geriatric team. ","PeriodicalId":87737,"journal":{"name":"Recent patents on CNS drug discovery","volume":"10 1","pages":"55-64"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574889810666150216152624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33385132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

Midkine and Pleiotrophin in the Treatment of Neurodegenerative Diseases and Drug Addiction. Midkine和Pleiotrophin在神经退行性疾病和药物成瘾治疗中的作用。

Recent patents on CNS drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574889810666150326103916

Luis F Alguacil, Gonzalo Herradón

引用次数: 13

Scientific Prediction and Prophetic Patenting in Drug Discovery. 药物发现中的科学预测和预言性专利申请。

Recent patents on CNS drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574889810666150619104344

Stephen H Curry, Anne M Schneiderman

{"title":"Scientific Prediction and Prophetic Patenting in Drug Discovery.","authors":"Stephen H Curry, Anne M Schneiderman","doi":"10.2174/1574889810666150619104344","DOIUrl":"https://doi.org/10.2174/1574889810666150619104344","url":null,"abstract":"Pharmaceutical patenting involves writing claims based on both discoveries already made, and on prophesy of future developments in an ongoing project. This is necessitated by the very different timelines involved in the drug discovery and product development process on the one hand, and successful patenting on the other. If patents are sought too early there is a risk that patent examiners will disallow claims because of lack of enablement. If patenting is delayed, claims are at risk of being denied on the basis of existence of prior art, because the body of relevant known science will have developed significantly while the project was being pursued. This review examines the role of prophetic patenting in relation to the essential predictability of many aspects of drug discovery science, promoting the concepts of discipline-related and project-related prediction. This is especially directed towards patenting activities supporting commercialization of academia-based discoveries, where long project timelines occur, and where experience, and resources to pay for patenting, are limited. The need for improved collaborative understanding among project scientists, technology transfer professionals in, for example, universities, patent attorneys, and patent examiners is emphasized.","PeriodicalId":87737,"journal":{"name":"Recent patents on CNS drug discovery","volume":"10 1","pages":"34-44"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574889810666150619104344","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33280422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histamine H₄ Receptor Antagonists: A New Approach for Tinnitus Treatment? 组胺H受体拮抗剂:治疗耳鸣的新途径?

Recent patents on CNS drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574889810666150424161907

Jens Hagenow, Holger Stark

引用次数: 2

Reperfusion Therapies in Acute Ischemic Stroke. 急性缺血性卒中的再灌注治疗。

Recent patents on CNS drug discovery Pub Date : 2015-01-01 DOI: 10.2174/1574889810666150701142836

Leonard L L Yeo, Benjamin Y Q Tan, Wan Yee, Amit Kulkarni, Vijay K Sharma

{"title":"Reperfusion Therapies in Acute Ischemic Stroke.","authors":"Leonard L L Yeo, Benjamin Y Q Tan, Wan Yee, Amit Kulkarni, Vijay K Sharma","doi":"10.2174/1574889810666150701142836","DOIUrl":"https://doi.org/10.2174/1574889810666150701142836","url":null,"abstract":"Acute Ischemic stroke (IS) remains a leading cause of mortality and long-term disability. Owing to the time-constraints, only a fraction of acute IS patients receive the established and approved thrombolytic therapy and a sizeable proportion of acute IS stroke survivors remain permanently disabled. Rapid advances in various recanalization strategies have aimed at improving functional outcome and reducing mortality. Existing literature on various treatment approaches, including the evolution of various thrombolytic agents and interventional devices is presented in this review. In addition to describing intravenous drug trials, continual developments in the field of trials for interventional devices have been described. Additionally, some of the important recent patents filed for various experimental approaches are presented. We strongly believe that the recent therapeutic approaches, including endovascular interventional strategies, based on advanced neuroimaging evaluations appear to have a promising future for acute IS patients. ","PeriodicalId":87737,"journal":{"name":"Recent patents on CNS drug discovery","volume":"10 1","pages":"45-54"},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574889810666150701142836","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33867406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Opinion Paper: Post-surgical Delirium, Consciousness, and Therapy. 意见书:术后谵妄、意识和治疗。

Recent patents on CNS drug discovery Pub Date : 2015-01-01 DOI: 10.2174/157488981001150727102501

Miao-Kun Sun

引用次数: 0

Antisense oligonucleotides in the treatment of cerebral gliomas. Review of concerning patents. 反义寡核苷酸治疗脑胶质瘤的研究。有关专利的审查。

Recent patents on CNS drug discovery Pub Date : 2014-04-01 DOI: 10.2174/1574889809666140307113439

Gerardo Caruso, Maria Caffo

引用次数: 13

Therapeutic potential of cannabinoids in schizophrenia. 大麻素对精神分裂症的治疗潜力。

Recent patents on CNS drug discovery Pub Date : 2014-04-01 DOI: 10.2174/1574889809666140307115532

Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Micale

{"title":"Therapeutic potential of cannabinoids in schizophrenia.","authors":"Jana Kucerova, Katarina Tabiova, Filippo Drago, Vincenzo Micale","doi":"10.2174/1574889809666140307115532","DOIUrl":"https://doi.org/10.2174/1574889809666140307115532","url":null,"abstract":"Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydrocannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoylglycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during pathophysiological conditions. In the brain, activation of this system impacts the release of numerous neurotransmitters in various systems and cytokines from glial cells. Hence, the endocannabinoid system is strongly involved in neuropsychiatric disorders, such as schizophrenia. Therefore, adolescence use of Cannabis may alter the endocannabinoid signalling and pose a potential environmental risk to develop psychosis. Consistently, preclinical and clinical studies have found a dysregulation in the endocannabinoid system such as changed expression of CB1 and CB2 receptors or altered levels of AEA and 2-AG . Thus, due to the partial efficacy of actual antipsychotics, compounds which modulate this system may provide a novel therapeutic target for the treatment of schizophrenia. The present article reviews current available knowledge on herbal, synthetic and endogenous cannabinoids with respect to the modulation of schizophrenic symptomatology. Furthermore, this review will be highlighting the therapeutic potential of cannabinoid-related compounds and presenting some promising patents targeting potential treatment options for schizophrenia. ","PeriodicalId":87737,"journal":{"name":"Recent patents on CNS drug discovery","volume":" ","pages":"13-25"},"PeriodicalIF":0.0,"publicationDate":"2014-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574889809666140307115532","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40291122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 60